Daniel Arber to Janus Kinase 2
This is a "connection" page, showing publications Daniel Arber has written about Janus Kinase 2.
Connection Strength
0.925
-
Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study. Am J Clin Pathol. 2024 Sep 03; 162(3):233-242.
Score: 0.236
-
Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Mod Pathol. 2021 01; 34(1):20-31.
Score: 0.177
-
Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. Mod Pathol. 2019 04; 32(4):490-498.
Score: 0.158
-
Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Mod Pathol. 2018 05; 31(5):690-704.
Score: 0.149
-
Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation. Leuk Res. 2023 04; 127:107033.
Score: 0.053
-
Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study. Mod Pathol. 2023 03; 36(3):100016.
Score: 0.053
-
The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol. 2023 01; 98(1):166-179.
Score: 0.052
-
Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. Blood Adv. 2021 09 14; 5(17):3492-3496.
Score: 0.048